Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

a will apply a portion of its medicinal chemistry resources to an unrelated BMS discovery program for up to three years. While the company is still evaluating the accounting treatment for its acquisition of the SARM program, it expects to record a non-cash charge to earnings ranging from $9.5 million to $10.0 million in the fourth quarter of 2007. This charge relates to the estimated fair value of the chemistry resources the company is to provide to BMS. In addition the company will pay BMS milestone payments associated with submission and approval of a therapeutic product for marketing and a stepped royalty on net sales of therapeutic products, if any, resulting from the SARM development program.

"Our recent clinical progress with PS433540 as well as the in-licensing of our new SARM program has significantly enhanced Pharmacopeia's pipeline," stated Les Browne, Ph.D., Pharmacopeia's President and Chief Executive Officer. "We now have two of our own programs in clinical development as well as two partnered programs advancing in Phase 2 clinical development that should yield results on efficacy in 2008."

THIRD QUARTER, 2007 FINANCIAL RESULTS

At September 30, 2007, Pharmacopeia had cash, cash equivalents and marketable securities of $81.4 million. As previously stated, Pharmacopeia expects to end the year with $65 million to $70 million in cash and short-term investments.

Pharmacopeia's net revenue was $5.1 million for the quarter ended September 30, 2007, compared to $6.3 million for the quarter ended September 30, 2006. The decrease in revenue during the quarter ended September 30, 2007 was primarily due to lower milestone revenue as compared to the prior year period, offset by increased research revenue from Pharmacopeia's alliances with GSK, Organon and Wyeth. For the nine months ended September 30, 2007, net revenue was $16.4 million, compared to $13.7 million for the same period in 2006. The increase in net revenue during the nine-month p
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Research and Markets  has announced the addition ... to their offering. Global Market Report of ... globally and regionally ( Europe , ... Latin America etc.). It captures Pralmorelin market ... focuses on three primary areas; manufacture methods & technology development, ...
(Date:8/20/2014)... , Aug. 20, 2014 Research ... the "Global Advanced Wound Care and Closure ... Size, Share, Global Trends, Company Profiles, Demand, Insights, ... - 2020" report to their offering. ... wound care and closure market (types, applications, end ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces that ... its catalogue: Global Coatings for Medical ... This report analyzes the worldwide ... Million by the following Product Segments: Active Coatings, ... report provides separate comprehensive analytics for the US, ...
Breaking Medicine Technology:Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21
... Calif., Oct. 11, 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ... designated the second development candidate, ISIS-AATRx, in its collaboration ... million milestone payment from GSK for the selection of ... liver disease caused by alpha-1 antitrypsin deficiency, or AATD, ...
... Va., Oct. 11, 2011 Innocoll, Inc. announces the ... of postoperative adhesions following abdominal and pelvic surgery. The ... of distribution partnerships. The company also plans to seek ... Canada, the MENA region, South East Asia, and to ...
Cached Medicine Technology:Isis Selects Development Candidate, Isis-AATRx, to Treat AATD-Associated Liver Disease 2Isis Selects Development Candidate, Isis-AATRx, to Treat AATD-Associated Liver Disease 3Isis Selects Development Candidate, Isis-AATRx, to Treat AATD-Associated Liver Disease 4Innocoll Announces European Approval for CollaGUARDĀ®, Surgical Adhesion Barrier 2Innocoll Announces European Approval for CollaGUARDĀ®, Surgical Adhesion Barrier 3
(Date:8/20/2014)... Ticket Down is a reliable source for authentic ... just a week, the U.S. Open Tennis Championship will kick off ... originally founded in 1881 and features grass courts since 1978. The ... from the event because of a wrist injury. Serena Williams was ... New York City with hopes of winning her sixth U.S. Open ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. ... dramatically during the past two decades, plummeting 57 percent and ... An estimated 4 million fewer births occurred among teenagers ... the U.S. Centers for Disease Control and Prevention. That ... report," said Bill Albert, chief program officer of The National ...
(Date:8/20/2014)... patient and tumor characteristics for melanomas with higher ... in an effort to increase earlier detection of ... , Author: Sarah Shen, M.B.B.S., B.Med.Sci., of Alfred ... The tumor characteristic known as mitotic rate ... prognosis and survival in melanoma patients. However, the ...
(Date:8/20/2014)... discovered that the immune system is defective in people suffering ... sufferers have ongoing issues with pain. , The research ... also help to explain why some painkillers may not offer ... up to 10% of the community. There are different ... pain, which often has the greatest impact on sufferers, quality ...
(Date:8/20/2014)... now, Free content, The time to deploy Ebola ... published early online today in Annals of ... of Public Health write that the relentless epidemiologic trajectory ... a public health crisis that shows no signs of ... developed in the last decade, yet the sporadic nature ...
Breaking Medicine News(10 mins):Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 2Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 4Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 5Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 2Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 3Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:Pain treatments less effective for those with irritable bowel 2Health News:News from Annals of Internal Medicine 2
... December 1, 2009 Adolescent obesity is a major public ... resulting in 4-5 million overweight youth in the United States. ... the Journal of the American Dietetic Association , researchers ... physical activity, comparing overweight adolescents who lost weight and those ...
... Being overweight as a child could lead to early degeneration in ... meeting of the Radiological Society of North America (RSNA). , "This ... mass index (BMI) and disc abnormalities in children," said the study,s ... The Children,s Hospital at Montefiore in New York City. , ...
... Dec. 1 High-frequency ultrasound with elastography can help ... a study presented today at the annual meeting of ... ultrasound with elastography has the potential to improve the ... L. Siegel, M.D., vice chairman of the Department of ...
... 30 HealthPlus of Michigan today announced the launch of ... people looking for affordable benefit choices and convenient access to ... highest-ranked Medicare plans in Michigan, according to the "America,s Best ... Report and the National Committee on Quality Assurance. , ...
... 30 In Massachusetts, approximately 70% of those with Alzheimer,s ... is preparing for a surge in calls to its 24/7 ... filled with opportunities for togetherness and sharing, but for a ... filled with special challenges, according to the experts at the ...
... Nov. 30 Kool Smiles received top honors for ... of InfoWorld ,s Top 100 IT Projects of 2009 ... a Wyse-based thin-client infrastructure to support the electronic health records systems ... this roll-out now complete, Kool Smiles has implemented electronic health records ...
Cached Medicine News:Health News:Investigators identify successful weight control strategies for adolescents 2Health News:Overweight Children may Develop Back Pain and Spinal Abnormalities 2Health News:Special Ultrasound Accurately Identifies Skin Cancer 2Health News:Special Ultrasound Accurately Identifies Skin Cancer 3Health News:HealthPlus Launches New Medicare Advantage Plans 2Health News:HealthPlus Launches New Medicare Advantage Plans 3Health News:Alzheimer's Caregivers Face Holiday Stress 2Health News:Kool Smiles Named Among 2009 InfoWorld 100 2
Express Elyte Systems....
... 2400 has minimal requirements ... low as 2 L/test) ... L/hour) thus maximizing operating ... rack handler facilitates continuous ...
Iron (Total/Ferene). Storage temp: 15 - 30 C. Linearity: 0 - 500 ug/dl. Expected values: from males 60 - 160 ug/dl, from females 43 - 140 ug/dl. Available with Calibrator and Number of test are 120....
Iron UIBC (UIBC Buffer + Color + Std.). An Automated analyzer test kits....
Medicine Products: